The U.S. Food Allergy Treatment Market remains highly dynamic due to developments within the industry in the area of biologic medicines, oral immunotherapy, and increased diagnostic accuracy that influences doctors' approach toward such a widespread disease. There are about 250 million people suffering from food allergies all over the world, and there may be various consequences for people including anaphylactic reactions that lead to death.
As reported by SNS Insider, the market size of the U.S. Food Allergy Treatment Market was USD 2.57 Billion in 2025 and is predicted to increase up to USD 6.08 Billion in 2035 due to high expenses on healthcare in the U.S., developed healthcare system, and a significant number of patients with peanut allergy (about 6.1 million people in America). It is connected to the bigger global Food Allergy Treatment Market valued at USD 7.57 Billion in 2025 and expected to grow to USD 18.29 Billion in 2035 at CAGR of 9.23%.
Gain Actionable Intelligence on Food Allergy Treatment Market – Request a Sample Report
Why the U.S. Leads Global Demand
The market of the United States is experiencing high growth due to the intensive spending on health care and good health care infrastructure. As per Food Allergy Research & Education, alone peanut allergy affects 6.1 million Americans, which provides excellent opportunities in the market for treatments of allergens.
North America was expected to earn 40.50% of global market revenues in 2025, out of which the contribution of the United States will be 84.80%. This shows the presence of many developers of treatments in the country, along with a good infrastructure for healthcare reimbursement.
Where U.S. Treatment Demand Is Concentrated
- Epinephrine is the leading drug type accounting for a market share of 41.00%, as it continues to serve as the first-line treatment in emergency scenarios involving acute allergic reactions.
- Biologics are the leading growing drug type due to the promising role of biologics such as Xolair in the process of desensitization therapy to peanut allergies and other food allergies.
- The parenteral route of administration accounts for 54.90% of all routes used in the treatment of food allergies as epinephrine injection serves as the standard emergency medication in case of anaphylaxis.
- The oral route of administration is the leading growing route since the approval of oral immunotherapy programs by the FDA.
- Peanuts are the leading type of allergens in terms of their demand, while tree nuts are the leading growing allergens.
- The hospitals are the leading end-users of products in question, while the homecare segment is the leading growing one.
A Market in Transition: Treatment Discontinuation Meets Biologics Expansion
The decision by Stallergenes Greer in August 2025 is to voluntarily phase out PALFORZIA by July 31, 2026, and there are no safety, quality or efficacy issues associated with it; however, it will work towards fulfilling regulatory obligations and ensuring a smooth transition of its patients. This leads to an immediate challenge for patients and providers in switching to other treatment methods but provides the opportunity to gain market share for newer biologics and oral immunotherapy products.
While balancing this, the FDA approved the use of Xolair in 2024 for the treatment of severe allergies in patients managing food allergy risks as well as other allergic reactions.
Companies Driving Innovation in the U.S. Market
Mitsubishi Gas Chemical
In 2024, Mitsubishi Gas Chemical and Alerje have collaborated to boost the allergy treatment sector worldwide, thus improving the accessibility of allergy treatment technology in the United States. Such cooperation helps in ensuring the access to allergy management technology at the time when the US market starts moving away from traditional oral immunotherapy treatments.
Novartis
In the presentation of its Q4 2025 results, Novartis mentioned that the start of the Phase III development process of remibrutinib is expected in H2 2026, thus building on its food allergy treatments portfolio. This further development will help Novartis benefit from the above-average growth of the biologics segment as people look for other solutions apart from epinephrine.
Intrommune Therapeutics
In 2024, Intrommune Therapeutics partnered with Inimmune to provide oral immunotherapy for patients with peanut allergy, utilizing the research expertise of both organizations toward common treatment objectives. The collaboration indicates the continuous drive of innovation in oral desensitization as other companies such as Stallergenes Greer have left certain product lines despite being market leaders in the field.
Examples of other market leaders in the United States include Sanofi, Genentech, GlaxoSmithKline, ARS Pharmaceuticals, and Aquestive Therapeutics.
Market Dynamics and Outlook
Growth Drivers
- Rising global prevalence of food allergies, affecting an estimated 250 million people worldwide
- Growing R&D investment in novel biological agents and desensitization therapies
- Increasing clinic visits and rising funding for allergy treatment research
Restraints
- Voluntary treatment discontinuations, such as Stallergenes Greer's PALFORZIA exit, creating patient transition disruption
- High costs of biologics and structured oral immunotherapy programs limiting adoption among price-sensitive populations
Opportunities
- Continued biologics pipeline expansion targeting food allergy desensitization beyond epinephrine-only management
- Growing diagnosis rates and dedicated treatment development for tree nut allergies
The Future of the U.S. Food Allergy Treatment Market
The U.S. market holds promise for growth up until 2035 owing to the increase in adoption of biologics, increase in number of home care treatment therapies, and continuous investment by pharmaceuticals in their clinical pipeline. Those companies which make it through the transition of PALFORZIA and also invest in biologics and therapies specific for tree nuts will fare well.
